Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
J Obstet Gynaecol ; 44(1): 2337691, 2024 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-38594870

RESUMO

BACKGROUND: Existing treatments for primary dysmenorrhoea (PD), such as NSAIDs, impart side effects. Ge-Gen decoction (GGD), a traditional Chinese medicine, has shown promise in treating PD, but its exact mechanisms remain unclear. Here, we aimed to investigate the efficiency of GGD in alleviating PD using a rat model to understand its precise mechanism of action. METHODS: We established a rat model of dysmenorrhoea induced by oestradiol and oxytocin. The PD rats were administered GGD or Ibuprofen (positive control) intragastrically once daily for seven consecutive days. Serum levels of prostaglandin E2 (PGE2), prostaglandin F2 alpha (PGF2α), ß-endorphin (ß-EP), thromboxane B2 (TXB2), 6-keto-prostaglandin F1α (6-keto-PGF1α) were determined using an enzyme-linked immunosorbent assay (ELISA). The expression levels of oestrogen receptor alpha (ERα) and cyclooxygenase-2 (COX-2) in uterine tissue were measured using immunohistochemical assays, and those of phosphorylated and total extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) were assessed using western blot analysis. RESULTS: Treatment with GGD significantly reduced writhing behaviour, histopathological scores, and levels of COX-2, PGE2, and PGF2α in the serum of PD rats. Additionally, GGD increased ß-EP content and inhibited ERK1/2 activation and ERα expression in uterine tissues. CONCLUSIONS: The results of this study suggest that GGD alleviates PD in rats by suppressing the COX-2-mediated release of PGE2 and PGF2α, modulating the ERα/ERK1/2/COX-2 pathway, and increasing ß-EP content. These results provide insights into the potential mechanisms of GGD in treating PD and support its further investigation as an alternative therapy for this condition.


Ge-Gen decoction is commonly used to alleviate primary dysmenorrhoea. However, its anti-dysmenorrhoea mechanism remains elusive. In this study, using a rat model of primary dysmenorrhoea, we demonstrate that Ge-Gen decoction reduced the levels of cyclooxygenase-2, prostaglandin E2, and prostaglandin F2 alpha in serum and phosphorylated extracellular signal-regulated protein kinases 1 and 2 in the uterus. These results suggest that Ge-Gen decoction alleviates primary dysmenorrhoea via inactivation of the oestrogen receptor alpha/extracellular signal-regulated protein kinases 1 and 2/cyclooxygenase-2 pathway. This study enhances our understanding of the pathogenesis of primary dysmenorrhoea and may potentially inform the development of novel treatment approaches.


Assuntos
Dismenorreia , Receptor alfa de Estrogênio , Humanos , Feminino , Ratos , Animais , Dismenorreia/tratamento farmacológico , Ciclo-Oxigenase 2/metabolismo , Ciclo-Oxigenase 2/uso terapêutico , Dinoprostona , Dinoprosta/uso terapêutico
2.
J Dermatolog Treat ; 32(4): 383-390, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31437059

RESUMO

BACKGROUND: Vitiligo is a chronic cutaneous disease characterized with hypopigmented patches that leave psychological impact on the patients. There is increasing need for new treatment modalities to shorten the duration of treatment of vitiligo with the least side effects. OBJECTIVE: To explore the effect of intralesional injection of prostaglandin F2α on the outcome of narrow band ultraviolet rays B (NBUVB) for patients with stable vitiligo. PATIENTS AND METHODS: The study included 27 stable vitiligo patients with overall symmetrical lesions. For each patient, one patch was treated with NBUVB alone (control side), while another symmetrical patch was treated with combined intralesional injection of prostaglandin F2α with NBUVB therapy, weekly for 3 months. RESULTS: There was statistically significant improvement in the repigmentation in the combination group compared with NBUVB group. Side effects were minimal. CONCLUSION: Intralesional injection of prostaglandin F2α in combination with NBUVB therapy could be considered as safe and tolerable technique for treatment of vitiligo, it shortens the duration of NBUVB therapy. Longer follow up is needed.


Assuntos
Dinoprosta/uso terapêutico , Terapia Ultravioleta/métodos , Vitiligo/terapia , Adolescente , Adulto , Criança , Terapia Combinada , Feminino , Humanos , Injeções Intralesionais , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Raios Ultravioleta , Vitiligo/tratamento farmacológico , Adulto Jovem
3.
Kaohsiung J Med Sci ; 22(6): 266-70, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16793563

RESUMO

The purpose of this study was to evaluate both the intraocular pressure (IOP)-decreasing and neuroprotective effects of Rescula (0.12% unoprostone isopropyl) as an alternative therapy to betablockers with a long-term drift effect in patients with glaucoma. Twenty-eight patients with unilateral or bilateral glaucoma were treated with Rescula instead of the original beta-blocker therapy. IOP was measured using a Goldmann applanation tonometer, and visual field defects were evaluated quantitatively by Humphrey automatic perimetry central 30-2 threshold test. The mean follow-up time was at least 1 year. Rescula achieved a significant (p = 0.00001) and long-lasting reduction in IOP (from 20.78 +/- 2.71 to 17.14 +/- 2.70 mmHg) in patients with open-angle glaucoma after 12 months of follow-up. It also demonstrated a significant (p = 0.02) IOP-reducing effect (from 20.67 +/- 3.60 to 16.36 +/- 3.67 mmHg) in patients with angle-closure glaucoma 12 months later. The mean deviation of visual field defects changed from -13.27 dB baseline to -10.64 dB at 12 months as evaluated by Humphrey field analyzer II central 30-2 threshold test after Rescula; however, there was no statistical difference (p = 0.098). Our results showed that Rescula has a significant IOP-reducing effect as an alternative therapy to beta-blockers with long-term drift effect in patients with open-angle and angle-closure glaucoma. However, a neuroprotective effect to prevent further progression of the visual field defect in patients with glaucoma was not demonstrated in this study.


Assuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Dinoprosta/análogos & derivados , Glaucoma/tratamento farmacológico , Adulto , Idoso , Dinoprosta/farmacologia , Dinoprosta/uso terapêutico , Feminino , Humanos , Pressão Intraocular/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Fármacos Neuroprotetores/farmacologia , Estudos Prospectivos , Campos Visuais/efeitos dos fármacos
4.
J Reprod Dev ; 52(3): 335-41, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16505595

RESUMO

Repeat breeding is one of the most important reproductive disorders in buffaloes. Its etiology, however, is not well described. The aim of this study was to show the clinical features of repeat breeding buffaloes referred to infertility camps in the southern region of Nepal. Eighty-five buffaloes mated three times or more without conception were clinically examined. Sixty percent of the buffaloes were heifers. Fifty-nine percent of the buffalo cows with repeat breeding were already 10 months or more after calving. Indications of cervicitis were observed in 25% of the repeat breeders. Buffalo cows 12 months or more after calving and heifers in adequate nutritional condition were treated with either GnRH or PGF2alpha, and showed a satisfactory conception rate after treatment. Cows within 12 months post partum and heifers at a relatively younger age were treated with a vitamin/mineral mixture supplement, and this resulted in a moderate conception rate. In conclusion, the major clinical features of repeat breeding buffaloes include a large proportion of heifers, a long interval from calving to treatment, a high incidence of cervicitis, and a high or moderate response to treatment with PGF2alpha and GnRH or vitamin/mineral mixture. More attention needs to be paid to estrous detection and management of mating with bulls.


Assuntos
Cruzamento , Búfalos , Infertilidade Feminina/tratamento farmacológico , Infertilidade Feminina/etiologia , Fatores Etários , Animais , Dinoprosta/uso terapêutico , Feminino , Hormônio Liberador de Gonadotropina/uso terapêutico , Infertilidade Feminina/veterinária , Nepal , Resultado do Tratamento , Cervicite Uterina , Vitaminas/uso terapêutico
5.
J Ocul Pharmacol Ther ; 20(5): 401-10, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15650515

RESUMO

Impairment of outflow facility in glaucoma causes large intraocular pressure (IOP) fluctuations that have been shown to be a risk factor for disease progression. The water-drinking provocative test (WDT) has been proposed as an indirect measurement of outflow facility to compare intraocular pressure responses of glaucoma eyes to different drugs. This study was a double-masked, randomized, parallel-group clinical trial comparing the IOP fluctuations in response to the WDT in patients using latanoprost versus unoprostone. After completing a wash-out of ocular hypotensive medications, patients with primary openangle glaucoma or ocular hypertension were randomized to receive either latanoprost (N=40) or unoprostone (N=42). IOP was measured before treatment and at 8 weeks after treatment (baseline IOP for WDT), followed by the WDT. IOP fluctuations and maximum IOP after water ingestion were compared between the two groups. Analysis of covariance was used to adjust for the effects of baseline IOP and treatment efficacy. The mean percentage reduction of IOP was 27% in patients using latanoprost, as compared to 13% in patients using unoprostone (p<0.001). Patients on treatment with latanoprost had significantly less IOP fluctuations in response to the WDT, compared to patients using unoprostone. From an overall baseline IOP of 20.0 mmHg and an overall treatment efficacy of 20%, the mean+/-standard error of the mean (SEM) of the IOP fluctuation during the WDT was 5.3+/-0.4 mmHg in the unoprostone group, and 3.6+/-0.4 mmHg in the latanoprost group (p=0.005, ANCOVA). This could represent an additional benefit of latanoprost over unoprostone in controlling the intraocular pressure of glaucomatous patients.


Assuntos
Anti-Hipertensivos/uso terapêutico , Dinoprosta/análogos & derivados , Dinoprosta/uso terapêutico , Ingestão de Líquidos , Glaucoma de Ângulo Aberto/tratamento farmacológico , Pressão Intraocular/efeitos dos fármacos , Prostaglandinas F Sintéticas/uso terapêutico , Método Duplo-Cego , Feminino , Humanos , Latanoprosta , Masculino , Pessoa de Meia-Idade , Hipertensão Ocular/tratamento farmacológico , Tonometria Ocular , Água
6.
Biol Pharm Bull ; 26(12): 1691-5, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-14646172

RESUMO

To find new prostanoid FP-receptor agonists possessing potent ocular-hypotensive effects with minimal side effects, we evaluated the agonistic activities of newly synthesized prostaglandin F(2alpha) derivatives for the prostanoid FP-receptor both in vitro and in vivo. The iris constrictions induced by the derivatives and their effects on melanin content were examined using cat isolated iris sphincters and cultured B16 melanoma cells, respectively. The effects of derivative ester forms on miosis and intraocular pressure (IOP) were evaluated in cats and cynomolgus monkeys, respectively. Of these derivatives, 6 out of 12 compounds were more potent iris constrictors, with EC(50) values of 0.6 to 9.4 nM, than a carboxylic acid of latanoprost (EC(50)=13.6 nM). A carboxylic acid of latanoprost (100 microM) significantly increased the melanin content of cultured B16 melanoma cells, but some 15,15-difluoro derivatives, such as AFP-157 and AFP-172, did not. Topically applied AFP-168, AFP-169 and AFP-175 (isopropyl ester, methyl ester and ethyl ester forms, respectively, of AFP-172) induced miosis in cats more potently than latanoprost. AFP-168 (0.0005%) reduced IOP to the same extent as 0.005% latanoprost (for at least 8 h). These findings indicate that 15,15-difluoroprostaglandin F(2alpha) derivatives, especially AFP-168, have more potent prostanoid FP-receptor agonistic activities than latanoprost. Hence, AFP-168 may be worthy of further evaluation as an ocular-hypotensive agent.


Assuntos
Dinoprosta/análogos & derivados , Dinoprosta/farmacologia , Pressão Intraocular/efeitos dos fármacos , Receptores de Prostaglandina/agonistas , Receptores de Prostaglandina/uso terapêutico , Administração Tópica , Animais , Gatos , Linhagem Celular Tumoral , Dinoprosta/administração & dosagem , Dinoprosta/farmacocinética , Dinoprosta/uso terapêutico , Avaliação Pré-Clínica de Medicamentos , Previsões , Pressão Intraocular/fisiologia , Iris/citologia , Iris/efeitos dos fármacos , Iris/fisiologia , Latanoprosta , Macaca fascicularis , Melaninas/antagonistas & inibidores , Melaninas/biossíntese , Camundongos , Miose/induzido quimicamente , Prostaglandinas F/administração & dosagem , Prostaglandinas F/farmacocinética , Prostaglandinas F/uso terapêutico , Prostaglandinas F Sintéticas/química , Prostaglandinas F Sintéticas/farmacologia
7.
Neurogastroenterol Motil ; 7(4): 199-210, 1995 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-8574908

RESUMO

Cyclical motor activity of the gastrointestinal tract, normally occurring during the interdigestive period in several mammals, is disrupted in the post-operative ileus. We determined the recovery from the disappearance of cyclical motor activity, from the stomach to the colon, in dogs after laparotomy with the force transducers. Moreover, we examined the effects of Leu13-motilin (KW-5139) and prostaglandin F2 alpha (PGF2 alpha), administered in the early post-operative period, on the gastrointestinal motility. Following laparotomy, the cyclical motor activity reappeared firstly in the ileum and the colon, then in the jejunum and the duodenum, and finally in the stomach. The reappearance time of the phase III contractions in the stomach was 105.8 +/- 10.6 h (n = 4). In the early post-operative period, KW-5139 (0.5 microgram kg-1, i.v.) induced phase-III-like contractions, whereas PGF2 alpha (50 micrograms kg-1, i.v.) induced simultaneously occurring contractions over the whole gastrointestine. The treatment with KW-5139 (0.5 microgram kg-1, i.v.) four times (twice daily on the first and the second post-operative day) significantly (P < 0.05) shortened the time required to recover the phase III contractions in the stomach (64.2 +/- 2.2 h, n = 4), whereas that with PGF2 alpha (50 micrograms kg-1, i.v.) four times did not (111.3 +/- 17.2 h, n = 4). The present results indicate that, after laparotomy, the cyclical motor activity recovers faster in the distal intestine than in the proximal intestine and the stomach, and that KW-5139, but not PGF2 alpha, shortens the reappearance time of the phase III activity in the stomach.


Assuntos
Dinoprosta/uso terapêutico , Motilidade Gastrointestinal/efeitos dos fármacos , Hormônios/uso terapêutico , Obstrução Intestinal/tratamento farmacológico , Obstrução Intestinal/fisiopatologia , Motilina/análogos & derivados , Complicações Pós-Operatórias/tratamento farmacológico , Complicações Pós-Operatórias/fisiopatologia , Análise de Variância , Animais , Fenômenos Biomecânicos , Cães , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Obstrução Intestinal/etiologia , Masculino , Motilina/uso terapêutico , Distribuição Aleatória , Estimulação Química
8.
Am J Vet Res ; 56(4): 468-72, 1995 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-7785824

RESUMO

Four intrauterine treatment strategies were evaluated for effectiveness in mares that were confirmed to be susceptible to chronic uterine infection. Pretreatment samples were obtained at detection of estrus, and a genital strain of Streptococcus zooepidemicus was infused into the uterus when a preovulatory (> 35 mm) follicle was detected. At 12 hours after inoculation, mares were assigned to 1 of 4 selected treatment groups: autologous plasma, 100 ml (n = 5); potassium penicillin, 5 million U in 100 ml of phosphate-buffered saline solution (PBSS; n = 5); 10 mg of prostaglandin F2 alpha in 100 ml of PBSS (n = 5)' and large-volume lavage with normal saline solution (1,000 ml increments). A fifth group, treated with vehicle alone (100 ml of PBSS), served as a negative control (n = 7). All treatments were administered into the uterus. To assess the effectiveness of the treatment, samples for culture and cytologic examination were collected at 96 hours after bacterial inoculation. An effect of treatment was observed on the number of uterine neutrophils (P = 0.02) and growth of S zooepidemicus (P < 0.01). Intrauterine treatment with potassium penicillin, prostaglandin F2 alpha, and large-volume uterine lavage significantly reduced the growth of S zooepidemicus (P < 0.01) as well as the number of neutrophils (P < 0.02). Autologous plasma reduced the number of neutrophils (P < 0.05), but not growth of S zooepidemicus. There was significant correlation between the number of uterine neutrophils and growth of S zooepidemicus for each treatment group (r = 0.57; P < 0.05).


Assuntos
Transfusão de Sangue Autóloga/veterinária , Dinoprosta/uso terapêutico , Doenças dos Cavalos , Infertilidade Feminina/veterinária , Penicilinas/uso terapêutico , Infecções Estreptocócicas/veterinária , Doenças Uterinas/veterinária , Análise de Variância , Animais , Biópsia/veterinária , Suscetibilidade a Doenças , Endométrio/patologia , Feminino , Cavalos , Infertilidade Feminina/complicações , Infertilidade Feminina/patologia , Neutrófilos/fisiologia , Infecções Estreptocócicas/prevenção & controle , Infecções Estreptocócicas/terapia , Streptococcus/efeitos dos fármacos , Streptococcus/crescimento & desenvolvimento , Irrigação Terapêutica/veterinária , Doenças Uterinas/prevenção & controle , Doenças Uterinas/terapia , Útero/microbiologia , Útero/patologia
9.
Stomatologiia (Mosk) ; 73(4): 13-5, 1994.
Artigo em Russo | MEDLINE | ID: mdl-7732521

RESUMO

Effects of prostaglandin F2 on the major components of the antioxidative system (levels of malonic dialdehyde and lipid peroxides, activities and content of glutathione enzymes and nonenzymes (glutathione peroxidase, glutathione reductase, and NADPH (NADH), oxidized and reduced glutathione) were studied in experiments with 60 dogs in which acute nonepidemic parotitis was modeled. A varying capacity of the cells of the parotid gland to resist the detrimental effects of the disease and specific features of prostaglandin F2 effect on this capacity were revealed: injection of prostaglandin F2 stimulated both lipid peroxidation and the activity of the antioxidative system and led to cellular injury in the presence of a relatively high level of cellular metabolism, preserving cellular viability on condition of inhibited rate of metabolic reactions, this being the principal factor for the parotid gland, among other factors determining the cytoprotective effect.


Assuntos
Antioxidantes , Dinoprosta/farmacologia , Peroxidação de Lipídeos/efeitos dos fármacos , Glândula Parótida/efeitos dos fármacos , Parotidite/tratamento farmacológico , Doença Aguda , Animais , Dinoprosta/uso terapêutico , Modelos Animais de Doenças , Cães , Avaliação Pré-Clínica de Medicamentos , Pancreatite/tratamento farmacológico , Pancreatite/metabolismo , Glândula Parótida/metabolismo , Parotidite/metabolismo
10.
J Vet Med Sci ; 55(4): 613-6, 1993 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-8399742

RESUMO

Moxibustion on 12 specific points (Keiketsu in Japanese) was applied for treatment of delayed uterine involution in 16 cows that were diagnosed on the basis of rectal palpation and vaginoscopic examination 21 to 35 days after parturition. The treatment was continued for three consecutive days. Other 32 cows with the delayed uterine involution were either injected intramuscularly with 25 mg PGF2 alpha (17 cows) or infused in utero with 500 mg ampicillin (15 cows). The uterine involution following the treatment was monitored by rectal palpation and vaginoscopic examination. Milk samples were collected three times weekly and used for milk progesterone assay to monitor the ovarian function. No significant difference was observed in the uterine involution among the groups treated with moxibustion, PGF2 alpha or ampicillin. Percentages of cows with abnormal cervical mucus and bacterial isolation from cervical swab decreased remarkably in all groups during 4 weeks after treatment. Forty-six percent of cows with delayed uterine involution was diagnosed as having inactive ovaries. Percentage of cows that responded with ovulation and corpus luteum formation after moxibustion was 67 percent, slightly higher than those in cows treated with PGF2 alpha or ampicillin. Reproductive performance after the moxibustion was well-comparable to those after PGF2 alpha or ampicillin treatment. Result indicates that the moxibustion could be used as the alternative to PGF2 alpha and antibiotics for treating delayed uterine involution in cows.


Assuntos
Doenças dos Bovinos , Moxibustão , Ovário/efeitos dos fármacos , Transtornos Puerperais/veterinária , Doenças Uterinas/veterinária , Útero/efeitos dos fármacos , Administração Tópica , Ampicilina/uso terapêutico , Animais , Bovinos , Dinoprosta/uso terapêutico , Feminino , Leite/química , Ovário/fisiologia , Gravidez , Progesterona/análise , Transtornos Puerperais/patologia , Transtornos Puerperais/terapia , Doenças Uterinas/patologia , Doenças Uterinas/terapia , Útero/fisiologia
11.
Am J Gastroenterol ; 87(2): 207-10, 1992 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-1734699

RESUMO

Two cases of vincristine-induced paralytic ileus are described, with therapeutic correlation. Both patients had a roentgenographic picture of paralytic ileus showing fecal mass in the ascending colon and dilated bowel loops. One patient was successfully treated with glycerin and saline enema through a fiberoptic colonoscope placed in the ascending colon. The second patient was successfully treated with intravenous prostaglandin F2 alpha (PGF2 alpha). Enema through a fiberoptic colonoscope or the intravenous administration of PGF2 alpha may, therefore, prove useful in the treatment of vincristine-induced gastrointestinal toxicity.


Assuntos
Pseudo-Obstrução do Colo/terapia , Colonoscopia , Dinoprosta/uso terapêutico , Enema/métodos , Vincristina/efeitos adversos , Pseudo-Obstrução do Colo/induzido quimicamente , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
12.
Artigo em Inglês | MEDLINE | ID: mdl-1445177

RESUMO

The serum albumin concentration and the albumin-globulin ratio had a significant effect on the rate of repeat breeding. In repeat breeders, low concentrations were found of albumin, progesterone, phosphorus, zinc, and glucose. The glycogen content of the cervical mucus was significantly lower in the repeat breeders. Treating repeat breeders with prostaglandin F2 alpha had positive effects on the parameter values.


Assuntos
Cruzamento , Doenças dos Bovinos/fisiopatologia , Dinoprosta/uso terapêutico , Infertilidade Feminina/veterinária , Reprodução , Animais , Glicemia/análise , Bovinos , Doenças dos Bovinos/sangue , Doenças dos Bovinos/tratamento farmacológico , Muco do Colo Uterino/química , Egito , Feminino , Globulinas/análise , Glicogênio/análise , Infertilidade Feminina/sangue , Infertilidade Feminina/tratamento farmacológico , Infertilidade Feminina/fisiopatologia , Masculino , Fósforo/sangue , Gravidez , Progesterona/sangue , Soroalbumina Bovina/análise , Zinco/sangue
13.
Probl Endokrinol (Mosk) ; 35(6): 54-8, 1989.
Artigo em Russo | MEDLINE | ID: mdl-2695918

RESUMO

The use of a synthetic peptide analog of LH-RH agonist--[D-Ala6, des Gly10, Pro9]-LH-RH ethylamide (surfagon) at microdoses and in short courses returned to normal the ovulatory cycle in the anovulatory condition in rats and caused luteinization of follicular cysts in rats and cows with further normalization of ovarian function. It is assumed that surfagon will be effective for the treatment of anovulatory condition and ovarian follicular cysts in women.


Assuntos
Cisto Folicular/tratamento farmacológico , Hormônio Liberador de Gonadotropina/análogos & derivados , Hormônios/uso terapêutico , Cistos Ovarianos/tratamento farmacológico , Animais , Anovulação/tratamento farmacológico , Anovulação/etiologia , Bovinos , Doenças dos Bovinos/tratamento farmacológico , Dinoprosta/uso terapêutico , Avaliação Pré-Clínica de Medicamentos/veterinária , Feminino , Cisto Folicular/etiologia , Cisto Folicular/veterinária , Hormônio Liberador de Gonadotropina/uso terapêutico , Hormônio Luteinizante/sangue , Cistos Ovarianos/etiologia , Cistos Ovarianos/veterinária , Ovariectomia , Ovário/patologia , Ratos , Ratos Endogâmicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA